human
rhinoviru
proteas
hrv
pro
known
promis
target
develop
therapeut
agent
common
cold
import
proteas
viral
replic
well
express
larg
number
serotyp
explor
nonpeptid
inhibitor
hrv
pro
seri
novel
heteroaromat
ester
synthes
evalu
inhibitori
activ
hrv
pro
determin
structureact
relationship
potent
inhibitor
group
ic
valu
nm
addit
bind
mode
novel
analog
moieti
explor
molecular
dock
suggest
new
interact
pocket
elsevi
ltd
right
reserv
picornavirus
includ
import
human
pathogen
human
rhinoviru
hrv
enteroviru
ev
coxsackieviru
cv
polioviru
pv
hepat
viru
hav
hrv
singl
major
caus
common
cold
popul
age
although
rhinoviru
infect
selflimit
complic
still
occur
patient
asthma
congest
heart
failur
bronchiectasi
cystic
fibrosi
date
agent
approv
fda
treatment
rhinoviru
infect
addit
larg
number
known
hrv
serotyp
make
vaccin
develop
difficult
clinic
treatment
direct
toward
relief
promin
symptom
clinic
syndrom
previou
work
antirhinovir
therapeut
agent
focus
princip
capsidbind
antipicornavir
compound
hrv
proteas
pro
inhibitor
hrv
pro
essenti
viru
replic
specif
catalyz
cleavag
glutamineglycin
peptid
bond
kda
viral
polyprotein
produc
cellular
translat
viral
rna
genom
hrv
pro
belong
cystein
proteas
famili
show
structur
similar
trypsin
proteas
share
minim
homolog
common
mammalian
enzym
import
enzym
viral
replic
high
conserv
enzym
activ
site
compon
known
hrv
serotyp
potent
select
hrv
pro
inhibitor
could
potenti
broadspectrum
antirhinovir
therapeut
agent
part
effort
develop
hrv
pro
inhibitor
peptidomimet
approach
wide
employ
base
activ
site
structur
cleavag
specif
date
one
peptidomimet
analog
rupintrivir
shown
figur
hrv
pro
inhibitor
advanc
stage
human
clinic
trial
phase
ii
clinic
trial
rupintrivir
show
intranas
deliveri
reduc
mean
total
daili
symptom
score
recent
sever
effort
develop
oral
bioavail
antirhinovir
agent
report
includ
rupintrivir
analog
improv
pharmacokinet
profil
nonpeptid
inhibitor
crystal
structur
sever
acut
respiratori
syndrom
sar
coronaviru
proteas
pro
reveal
high
similar
activ
site
architectur
hrv
pro
suggest
picornaviru
pro
sar
pro
inhibitor
crossreact
fact
sar
pro
inhibitor
develop
modifi
rupintrivir
common
inhibitor
ic
valu
micromolar
rang
recent
identifi
picornaviru
pro
coronaviru
pro
use
highthroughput
screen
pyridinyl
thiophen
ester
discov
screen
small
molecul
librari
molecul
signific
inhibitori
activ
hav
pro
sar
pro
ic
lm
work
seri
heteroaromat
ester
result
discoveri
potent
ester
inhibit
sar
pro
ic
nm
antivir
activ
ec
valu
lm
anoth
analog
also
show
potent
inhibit
hav
pro
ic
nm
studi
inhibitori
molecular
dock
mechan
heteroaromat
ester
shown
moieti
crucial
bind
pocket
pro
pro
show
high
specif
gln
residu
see
front
matter
human
rhinoviru
proteas
hrv
pro
known
promis
target
develop
therapeut
agent
common
cold
import
proteas
viral
replic
well
express
larg
number
serotyp
explor
nonpeptid
inhibitor
hrv
pro
seri
novel
heteroaromat
ester
synthes
evalu
inhibitori
activ
hrv
pro
determin
structureact
relationship
potent
inhibitor
group
ic
valu
nm
addit
bind
mode
novel
analog
moieti
explor
molecular
dock
suggest
new
interact
pocket
elsevi
ltd
right
reserv
picornavirus
includ
import
human
pathogen
human
rhinoviru
hrv
enteroviru
ev
coxsackieviru
cv
polioviru
pv
hepat
viru
hav
hrv
singl
major
caus
common
cold
popul
age
although
rhinoviru
infect
selflimit
complic
still
occur
patient
asthma
congest
heart
failur
bronchiectasi
cystic
fibrosi
date
agent
approv
fda
treatment
rhinoviru
infect
addit
larg
number
known
hrv
serotyp
make
vaccin
develop
difficult
clinic
treatment
direct
toward
relief
promin
symptom
clinic
syndrom
previou
work
antirhinovir
therapeut
agent
focus
princip
capsidbind
antipicornavir
compound
hrv
proteas
pro
inhibitor
hrv
pro
essenti
viru
replic
specif
catalyz
cleavag
glutamineglycin
peptid
bond
kda
viral
polyprotein
produc
cellular
translat
viral
rna
genom
hrv
pro
belong
cystein
proteas
famili
show
structur
similar
trypsin
proteas
share
minim
homolog
common
mammalian
enzym
import
enzym
viral
replic
high
conserv
enzym
activ
site
compon
known
hrv
serotyp
potent
select
hrv
pro
inhibitor
could
potenti
broadspectrum
antirhinovir
therapeut
agent
part
effort
develop
hrv
pro
inhibitor
peptidomimet
approach
wide
employ
base
activ
site
structur
cleavag
specif
date
one
peptidomimet
analog
rupintrivir
shown
figur
hrv
pro
inhibitor
advanc
stage
human
clinic
trial
phase
ii
clinic
trial
rupintrivir
show
intranas
deliveri
reduc
mean
total
daili
symptom
score
recent
sever
effort
develop
oral
bioavail
antirhinovir
agent
report
includ
rupintrivir
analog
improv
pharmacokinet
profil
nonpeptid
inhibitor
crystal
structur
sever
acut
respiratori
syndrom
sar
coronaviru
proteas
pro
reveal
high
similar
activ
site
architectur
hrv
pro
suggest
picornaviru
pro
sar
pro
inhibitor
crossreact
fact
sar
pro
inhibitor
develop
modifi
rupintrivir
common
inhibitor
ic
valu
micromolar
rang
recent
identifi
picornaviru
pro
coronaviru
pro
use
highthroughput
screen
pyridinyl
thiophen
ester
discov
screen
small
molecul
librari
molecul
signific
inhibitori
activ
hav
pro
sar
pro
ic
lm
work
seri
heteroaromat
ester
result
discoveri
potent
ester
inhibit
sar
pro
ic
nm
antivir
activ
ec
valu
lm
anoth
analog
also
show
potent
inhibit
hav
pro
ic
nm
studi
inhibitori
molecular
dock
mechan
heteroaromat
ester
shown
moieti
crucial
bind
pocket
pro
pro
show
high
specif
gln
residu
herein
report
structureact
relationship
heteroaromat
ester
respect
inhibitori
activ
hrv
pro
thirtyon
heteroaromat
ester
includ
newli
design
deriv
synthes
screen
hrv
pro
use
fluoresc
peptid
substrat
also
perform
molecular
dock
studi
understand
potenti
inhibitor
bind
mode
activ
site
hrv
pro
gener
synthet
method
heteroaromat
ester
describ
scheme
seri
compound
synthes
esterif
variou
carboxyl
acid
hydroxyheteroaromat
group
initi
replac
pyridin
moieti
variou
heteroaromat
ring
perform
retent
group
commerci
avail
hydroxyheteroaromat
ring
esterifi
chlorid
pyridin
ch
cl
compound
prepar
two
step
scheme
structur
inhibitori
activ
analog
shown
tabl
second
seri
analog
ester
use
bromo
esterif
divers
carboxyl
acid
moieti
compound
prepar
commerci
avail
carboxyl
acid
compound
synthes
aryl
nh
group
imidazol
ring
reaction
boron
acid
follow
pyridin
use
cupric
acet
molecular
siev
ch
cl
synthesi
oxazolecarboxyl
acid
compound
outlin
scheme
briefli
acyl
diethyl
malon
use
variou
acid
chlorid
follow
dehydr
cycliz
employ
trifluoroacet
anhydrid
trichloroacetyl
chlorid
microwav
condit
min
afford
oxazol
subject
basic
hydrolysi
yield
correspond
oxazolecarboxyl
acid
structur
activ
ester
analog
shown
tabl
fretbas
assay
system
use
measur
enzym
activ
pro
express
cdna
use
fluorogen
substrat
nmnalfqgppvkdnp
shown
tabl
moieti
compound
repres
analog
heteroaromat
inhibitor
replac
variou
heteroaromat
group
furon
show
weak
inhibit
hrv
pro
inhibit
lm
wherea
furon
show
inhibitori
effect
chloroand
bromosubstitu
posit
pyridinyl
ring
significantli
increas
inhibitori
effect
compound
compound
show
potent
activ
ic
valu
nm
ester
function
well
hrv
pro
inhibitor
result
pocket
similar
hav
pro
sar
pro
molecular
dock
compound
activ
site
xray
crystal
structur
hrv
pro
pdb
perform
charmm
forc
field
base
dock
tool
cdocker
discoveri
studio
accelri
inc
san
diego
ca
rigid
receptor
structur
random
orient
ligand
conform
subject
simul
anneal
molecular
dynam
final
minim
pose
dock
ligand
sort
charmm
energi
interact
energi
plu
ligand
strain
mass
spectrometri
hplc
studi
alreadi
reveal
inhibit
mechan
heteroaromat
ester
act
activ
site
sar
ester
initi
bind
competit
strongli
activ
site
recogn
pocket
carbonyl
carbon
attack
nucleophil
cy
residu
becom
coval
connect
proteas
prior
eventu
releas
thu
studi
possibl
prehydrolysisbind
complex
model
gener
fig
lone
pair
electron
nitrogen
moieti
occupi
bind
pocket
form
hydrogen
bond
n
bromo
group
occupi
pocket
near
protein
surfac
notabl
hydrogen
bond
nh
observ
explain
import
presenc
halogen
group
pyridin
ring
ester
carbonyl
oxygen
form
hydrogen
bond
nh
predict
bind
model
consist
bind
mode
halopyridinyl
ester
sar
pro
hav
pro
explor
possibl
new
bind
interact
new
motiv
substitut
pyridin
ring
design
point
toward
n
pocket
therefor
pyridinyl
compound
investig
amin
amid
substitut
compound
show
moder
activ
lm
absenc
chlorin
posit
new
pocket
bind
moieti
also
evalu
use
para
meta
benzamid
instead
compound
may
possibl
mimic
gln
substrat
cleavag
moieti
show
weak
inhibitiori
effect
inhibit
lm
inhibit
lm
notabl
compound
show
potent
inhibitori
effect
lm
inhibit
ic
valu
nm
gain
molecular
insight
bind
mode
moieti
compound
also
dock
hrv
pro
activ
site
fig
oxygen
quinolinon
form
hydrogen
bond
n
benzen
ring
quinolinon
occupi
outer
space
pocket
bromo
group
hydrogen
bond
nh
hydrogen
bond
ester
carbonyl
oxygen
nh
also
conserv
well
although
differ
spatial
posit
carbonyl
oxygen
pyridyl
nitrogen
requir
hydrogen
bond
angl
carbonyl
oxygen
n
satisfi
ideal
hydrogen
bond
c
axi
within
carbonyl
plane
sp
lone
pair
pyridyl
nitrogen
lie
toward
n
form
optim
hydrogen
bond
angl
precis
hydrogen
bond
seem
key
initi
bind
unit
mimic
gln
moieti
residu
result
dramat
inhibitori
activ
chang
depend
substitu
r
interact
energi
compound
pro
calcul
cdocker
program
potent
compound
show
kcalmol
respect
comparison
interact
energi
ortho
kcalmol
meta
kcalmol
para
kcalmol
posit
pyridin
nitrogen
show
parallel
result
biolog
activ
suggest
meta
posit
could
prefer
orient
hydrogen
bond
compound
addit
hydrogen
bond
acceptor
pyridin
ring
might
disturb
optim
hydrogen
bond
pyridyl
nitrogen
show
less
interact
energi
kcalmol
kcalmol
although
weak
inhibitor
benzamid
analog
could
form
hydrogen
bond
kcalmol
kcal
mol
distanc
ester
carbonyl
carbon
nucleophil
sh
group
cy
might
chang
unfavor
result
weak
inhibitori
activ
search
effect
moieti
group
seri
ester
variou
carboxyl
acid
synthes
test
r
carboxyl
acid
expect
provid
site
specif
hydrophob
pocket
affect
coval
connect
bind
mode
activ
site
compound
show
moderatetogood
inhibitori
effect
lm
except
tabl
compound
benzoyl
phenylpropanoyl
group
cinnamoyl
show
lower
activ
analog
substitut
posit
furan
ring
aromat
group
allow
retent
good
activ
steric
effect
addit
aromat
group
could
stabil
postreact
state
pstack
interact
rather
tight
bind
pocket
imidazol
group
use
build
block
show
potent
inhibitori
activ
ic
nm
howev
aryl
imidazol
ring
show
twofold
decreas
activ
could
caus
unfavor
constraint
compar
furan
ring
effort
replac
furoyl
ring
heterocycl
carboxyl
moieti
isoxazol
oxazol
group
investig
case
deriv
replac
posit
furan
oxygen
carbon
atom
result
loss
activ
significantli
howev
oxazol
deriv
demonstr
broad
rang
inhibitori
activ
depend
substitut
posit
oxazol
group
cinnamyloxazol
analog
show
highest
activ
among
compound
inhibit
lm
ic
valu
nm
lower
electron
densiti
oxazol
ring
may
result
weaker
bind
affin
furan
imidazol
moieti
addit
hydrophob
phenyl
group
proper
posit
connect
posit
two
carbon
chain
significantli
enhanc
inhibitori
activ
compar
compound
shorter
chain
bulki
aromat
group
conclus
heteroaromat
ester
synthes
screen
nonpeptid
inhibitor
hrv
pro
compound
one
potent
inhibitor
earlier
seri
activ
sar
pro
hav
pro
also
found
potent
current
work
ic
nm
substitut
variou
heteroaromat
ring
result
discoveri
group
altern
key
structur
optim
ester
analog
gln
skeleton
mimic
underway
aim
enhanc
inhibitori
activ
